Recipharm Makes Two New Appointments
This article was originally published in Scrip
Recipharm, a contract development and manufacturing organisation, has appointed Franco Boselli business director in Italy and Bernard Pluta general manager for the operating company in Pessac, France. Prior to joining Recipharm, Boselli worked in marketing and sales in Italian pharmaceutical companies and was previously business development director at Biologici Italia Laboratories. Before this he was business development manager in an Italian CMO, Mipharm. Pluta has previously held executive positions in Theramex and Teva and currently runs his own CMO consultancy business.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.